16 completed, 7 not yet recruiting, 6 unknown, 5 recruiting. 39 Phase 2, 2 Phase 1, 2 Phase 3.
Follow CP protocol: new trials by email Literature Review of CP protocol trials Research Report on CP protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCC Toripalimab, Carboplatin + Paclitaxel - Esophageal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | Vanderbilt-Ingram Cancer Center | 20 | 2026-12-31 | 2026-09-23 |
| Blood and imagE-guided Optimization of Neoadjuvant Therapy in People With Early Stage Triple-negative Breast cancER - the BETTER Trial Paclitaxel + Carboplatin, Pembrolizumab - Triple Negative Breast Cancer, Blood and Image Guided | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 200 | 2026-11-05 | 2026-05-28 |
| Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer Trastuzumab Rezetecan (SHR-A1811), Carboplatin, Bevacizumab - Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC) | Phase 2 | Not yet recruiting | Sun Yat-sen University | 176 | 2026-09-30 | 2026-08-20 |
| Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer Eftilagimod Alfa (Efti), Docetaxel-cyclophosphamide (TC) intravenous (i.v), Dose dense Adriamycin-cyclophosphamide (AC) i.v - Breast Cancer, HER 2 Negative Breast Cancer | Phase 2 | Not yet recruiting | George Washington University | 50 | 2026-09-01 | 2026-06-11 |
| A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. EIK1001, Pembrolizumab (KEYTRUDA®), Placebo - Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC | Phase 2 / Phase 3 | Recruiting | Eikon Therapeutics | 750 | 2026-06-15 | 2026-11-03 |
| Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer Hypofractionation, carboplatin + paclitaxel (CP) - Locally Advanced Esophageal or GE Junction Cancer | Phase 2 | Recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 60 | 2026-04-28 | 2026-06-08 |
| The Efficacy and Safety of Paclitaxel Monotherapy Versus Paclitaxel-Carboplatin Combination as Neoadjuvant Chemotherapy in Advanced Ovarian Cancer With High PARK2 Expression Paclitaxel, Paclitaxel + Carboplatin - Ovarian Cancer | Phase 2 | Not yet recruiting | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 60 | 2026-01-31 | 2026-02-10 |
| A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients SSGJ-706, pemetrexed /carboplatin, Carboplatin/Paclitaxel - First-line Advanced NSCLC Patients | Phase 2 | Recruiting | Shenyang Sunshine Pharmaceutical Co., LTD. | 240 | 2025-10-24 | 2025-12-18 |
| Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer Camrelizumab, Doxorubicin +cyclophosphamide+ filgrastimum, carboplatin + paclitaxel (CP) - Breast Cancer | Phase 2 | Not yet recruiting | Blokhin's Russian Cancer Research Center | 40 | 2025-08-01 | 2025-08-17 |
| Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer Cyclophosphamide+Pemetrexed+5-Fluorouracil, Cyclophosphamide+Doxorubicin+5-Fluorouracil, Vindesine + Cisplatin - Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer | Phase 2 | Not yet recruiting | West China Hospital | 20 | 2024-12-01 | 2024-12-03 |
| Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer Carboplatin/Paclitaxel, Pembrolizumab, Partial or total penectomy with inguinal and/or pelvic lymph node dissection - Urologic Neoplasms, Urogenital Neoplasms | Phase 2 | Recruiting | The Netherlands Cancer Institute | 27 | 2024-08-13 | 2025-12-08 |
| Trial of Neoadjuvant Therapy With Paclitaxel and Carboplatin in Operable Locally Advanced Head and Neck Cancer Patients paclitaxel/carboplatin - Head and Neck Squamous Cell Carcinoma | Phase 2 | Completed | Yonsei University | 79 | 2023-05-26 | 2026-05-26 |
| Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer Durvalumab, Oleclumab, Monalizumab - Non-small Cell Lung Cancer | Phase 2 | Recruiting | AstraZeneca | 630 | 2022-04-14 | 2026-10-21 |
| Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer Drug: Anlotinib, Drug: Carboplatin/Paclitaxel - Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Active not recruiting | Wenjun Cheng | 56 | 2021-08-24 | 2024-07-03 |
| A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC Durvalumab, Carboplatin/ Paclitaxel, Pemetrexed/ Cisplatin - Unresectable Stage III NSCLC | Phase 2 | Unknown | Shandong Cancer Hospital and Institute | 35 | 2021-01-21 | 2021-08-06 |
| Carboplatin-Paclitaxel Adjuvant Chemotherapy in the Treatment of Locally Advanced Cervical Cancer Carboplatin-Paclitaxel adjuvant chemotherapy - Locally Advanced Cancer, Cervical Cancer | Phase 2 | Terminated | Centre Oscar Lambret | 21 | 2020-07-15 | 2026-03-18 |
| Uterine Serous Carcinoma and Adjuvant Combined Intraperitoneal Chemotherapy and Radiation Paclitaxel/Carboplatin, Pelvic radiation therapy - Uterine Carcinoma | Phase 1 / Phase 2 | Withdrawn | Northwell Health | 2020-05-20 | 2023-03-17 | |
| Adjuvant Palbociclib in Elderly Patients With Breast Cancer Palbociclib, Docetaxel / cyclophosphamide, doxorubicin/cyclophosphamide - Breast Cancer Stage II, Breast Cancer Stage III | Phase 2 | Active not recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 366 | 2019-06-14 | 2026-05-12 |
| Phase II Trial of Neoadjuvant Treatment and Minimal Invasive Surgery for Esophageal and GEJ Cancer carboplatin paclitaxel - Esophageal Cancer, Induction Chemotherapy | Phase 2 | Unknown | Instituto Nacional de Cancer, Brazil | 50 | 2017-02-01 | 2018-03-20 |
| Nivolumab in Combination With Ipilimumab (Part 1); Nivolumab Plus Ipilimumab in Combination With Chemotherapy (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer Nivolumab, Ipilimumab, Platinum Doublet Chemotherapy - Non-Small-Cell Lung Cancer | Phase 2 | Completed | Bristol-Myers Squibb | 324 | 2016-02-15 | 2023-04-05 |
Showing 20 of 39. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (11) · Breast Neoplasms (5) · Ovarian Neoplasms (3) · Adenocarcinoma (2) · Carcinoma (2) · Carcinoma, Ovarian Epithelial (2) · Esophageal Neoplasms (2) · Lung Neoplasms (2) · Neoplasms, Unknown Primary (2) · Uterine Cervical Neoplasms (2) · Uterine Neoplasms (2) · Adenocarcinoma Of Esophagus (1) · Anemia (1) · Bulbo-Spinal Atrophy, X-Linked (1) · Endocrine System Diseases (1)
European Organisation for Research and Treatment of Cancer - EORTC (2) · Abbott (1) · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1) · Asan Medical Center (1) · AstraZeneca (1) · Beijing Protgen Biotechnology Development Co., Ltd. (1) · Blokhin's Russian Cancer Research Center (1) · Bristol-Myers Squibb (1) · Cairo University (1) · Centre Oscar Lambret (1) · Dr. Gordon Buduhan (1) · Eikon Therapeutics (1) · George Washington University (1) · Heidelberg University (1) · Instituto Nacional de Cancer, Brazil (1)
China (11) · United States (11) · Belgium (5) · France (5) · Germany (5) · South Korea (5) · Canada (4) · Italy (3) · Netherlands (3) · Spain (3) · Australia (2) · Austria (2) · Brazil (2) · Greece (2) · Hungary (2)
Alessandro D Santin, M.D. (1) · Alwin Kraemer, Prof. Dr. (1) · Andreas Obermair (1) · Clinton Yam, MD (1) · Florence Le Tinier, MD (1) · Gordon Buduhan, MD MSc FRCSC (1) · Hans Wildiers, MD, PhD (1) · Imran Ahmad, MD (1) · John M. Straughn, MD (1) · Karin Shih, MD (1) · Kevin Harrington (1) · Kunwei Shen, Dr (1) · Lisa Licitra (1)
PMID 11020574, PMID 15169803, PMID 15459211, PMID 15913742, PMID 16330675, PMID 1989916, PMID 20211870, PMID 21436701, PMID 21508697, PMID 2211199, PMID 2211200, PMID 2258085, PMID 2323606, PMID 23642625, PMID 2380095, PMID 2412690, PMID 24724218, PMID 26493267, PMID 27067521, PMID 2745205, PMID 29584549, PMID 3053592, PMID 30785829, PMID 32601075, PMID 33235314, PMID 40450142, PMID 4055452, PMID 6999399, PMID 7102898, PMID 7617840, PMID 7729725, PMID 8088602, PMID 8381710, PMID 8490920, PMID 8522260, PMID 8751561, PMID 8859187
2018 (1), 2023 (1), 2025 (1)